<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055805</url>
  </required_header>
  <id_info>
    <org_study_id>VIL-HEQ-17-014</org_study_id>
    <nct_id>NCT04055805</nct_id>
  </id_info>
  <brief_title>Health and QoL in Oncological Patients: Management of Bone Pathology in Italian Citbl Population</brief_title>
  <official_title>Health and Quality of Life in Oncological Patients: Management of Bone Pathology in the Italian Citbl (Cancer Treatment Induced Bone Loss) Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studying the current state of the clinical approaches to bone diseases in breast cancer
      patients treated with adjuvant and/or hormone therapy
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2018</start_date>
  <completion_date type="Anticipated">October 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 26, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Results from some questionnaires related to patients QoL, rated from 1 to 10.</measure>
    <time_frame>26-32 months</time_frame>
    <description>Description of the current state of the most frequent clinical and therapeutical approaches to bone diseases in 700 breast cancer menopausal patients treated with adjuvant and/or hormonal therapy. These patients are assessed by questionnaires regarding quality of life, menopausal status and current anti resorptive treatments</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Fondazione Policlinico Universitario A. Gemelli, Roma</arm_group_label>
    <description>Polo Scienze della Salute della Donna e del Bambino</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Università degli Studi di Pavia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Università di Napoli &quot;Federico II&quot;</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Università degli Studi di Siena</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Azienda Ospedaliero-Universitaria Careggi Firenze</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Fondazione Policlinico Universitario A. Gemelli Roma</arm_group_label>
    <description>U.O.C Chirurgia Senologica</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Istituto Nazionale dei Tumori di Napoli Fondazione G.Pascale</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Observational Analysis</intervention_name>
    <description>Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy</description>
    <arm_group_label>Azienda Ospedaliero-Universitaria Careggi Firenze</arm_group_label>
    <arm_group_label>Fondazione Policlinico Universitario A. Gemelli Roma</arm_group_label>
    <arm_group_label>Fondazione Policlinico Universitario A. Gemelli, Roma</arm_group_label>
    <arm_group_label>Istituto Nazionale dei Tumori di Napoli Fondazione G.Pascale</arm_group_label>
    <arm_group_label>Università degli Studi di Pavia</arm_group_label>
    <arm_group_label>Università degli Studi di Siena</arm_group_label>
    <arm_group_label>Università di Napoli &quot;Federico II&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women affected by breast cancer in menopause or with secondary amenorrhea arising from the
        initiation of oncologic treatments
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients willing to provide the Informed consent to participate to the study

          -  Women aged 18-75 years

          -  Patients having breast cancer, with no phenotype restrictions

          -  Patients in natural and stable menopause

          -  Patients having secondary amenorrhea, that arose after the initiation of oncologic
             treatment, since at least 12 months or 6 months with FSH&gt; 40 U/I

        Exclusion Criteria:

          -  Patients with advanced cancer and/or bone metastases and/or visceral metastases

          -  Patients with severe renal insufficiency and/or in dialysis and patients affected by
             severe endocrine disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paola Villa, Md PhD</last_name>
    <phone>+393392318208</phone>
    <email>paola.villa@policlinicogemelli.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Villa, MD, PhD</last_name>
      <phone>+393392318208</phone>
      <email>paola.villa@policlinicogemelli.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>August 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</investigator_affiliation>
    <investigator_full_name>Dr.ssa Paola Villa</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Aromatase Inhibitors</keyword>
  <keyword>Bone pathology</keyword>
  <keyword>QoL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

